Cargando…

A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol

The development of radiation countermeasures for acute radiation syndrome (ARS) has been underway for the past six decades, leading to the identification of multiple classes of radiation countermeasures. However, to date, only two growth factors (Neupogen and Neulasta) have been approved by the Unit...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheema, Amrita K., Mehta, Khyati Y., Fatanmi, Oluseyi O., Wise, Stephen Y., Hinzman, Charles P., Wolff, Josh, Singh, Vijay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796029/
https://www.ncbi.nlm.nih.gov/pubmed/29283379
http://dx.doi.org/10.3390/ijms19010079
_version_ 1783297416280145920
author Cheema, Amrita K.
Mehta, Khyati Y.
Fatanmi, Oluseyi O.
Wise, Stephen Y.
Hinzman, Charles P.
Wolff, Josh
Singh, Vijay K.
author_facet Cheema, Amrita K.
Mehta, Khyati Y.
Fatanmi, Oluseyi O.
Wise, Stephen Y.
Hinzman, Charles P.
Wolff, Josh
Singh, Vijay K.
author_sort Cheema, Amrita K.
collection PubMed
description The development of radiation countermeasures for acute radiation syndrome (ARS) has been underway for the past six decades, leading to the identification of multiple classes of radiation countermeasures. However, to date, only two growth factors (Neupogen and Neulasta) have been approved by the United States Food and Drug Administration (US FDA) for the mitigation of hematopoietic acute radiation syndrome (H-ARS). No radioprotector for ARS has been approved by the FDA yet. Gamma-tocotrienol (GT3) has been demonstrated to have radioprotective efficacy in murine as well as nonhuman primate (NHP) models. Currently, GT3 is under advanced development as a radioprotector that can be administered prior to radiation exposure. We are studying this agent for its safety profile and efficacy using the NHP model. In this study, we analyzed global metabolomic and lipidomic changes using ultra-performance liquid chromatography (UPLC) quadrupole time-of-flight mass spectrometry (QTOF-MS) in serum samples of NHPs administered GT3. Our study, using 12 NHPs, demonstrates that alterations in metabolites manifest only 24 h after GT3 administration. Furthermore, metabolic changes are associated with transient increase in the bioavailability of antioxidants, including lactic acid and cholic acid and anti-inflammatory metabolites 3 deoxyvitamin D3, and docosahexaenoic acid. Taken together, our results show that the administration of GT3 to NHPs causes metabolic shifts that would provide an overall advantage to combat radiation injury. This initial assessment also highlights the utility of metabolomics and lipidomics to determine the underlying physiological mechanisms involved in the radioprotective efficacy of GT3.
format Online
Article
Text
id pubmed-5796029
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57960292018-02-09 A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol Cheema, Amrita K. Mehta, Khyati Y. Fatanmi, Oluseyi O. Wise, Stephen Y. Hinzman, Charles P. Wolff, Josh Singh, Vijay K. Int J Mol Sci Article The development of radiation countermeasures for acute radiation syndrome (ARS) has been underway for the past six decades, leading to the identification of multiple classes of radiation countermeasures. However, to date, only two growth factors (Neupogen and Neulasta) have been approved by the United States Food and Drug Administration (US FDA) for the mitigation of hematopoietic acute radiation syndrome (H-ARS). No radioprotector for ARS has been approved by the FDA yet. Gamma-tocotrienol (GT3) has been demonstrated to have radioprotective efficacy in murine as well as nonhuman primate (NHP) models. Currently, GT3 is under advanced development as a radioprotector that can be administered prior to radiation exposure. We are studying this agent for its safety profile and efficacy using the NHP model. In this study, we analyzed global metabolomic and lipidomic changes using ultra-performance liquid chromatography (UPLC) quadrupole time-of-flight mass spectrometry (QTOF-MS) in serum samples of NHPs administered GT3. Our study, using 12 NHPs, demonstrates that alterations in metabolites manifest only 24 h after GT3 administration. Furthermore, metabolic changes are associated with transient increase in the bioavailability of antioxidants, including lactic acid and cholic acid and anti-inflammatory metabolites 3 deoxyvitamin D3, and docosahexaenoic acid. Taken together, our results show that the administration of GT3 to NHPs causes metabolic shifts that would provide an overall advantage to combat radiation injury. This initial assessment also highlights the utility of metabolomics and lipidomics to determine the underlying physiological mechanisms involved in the radioprotective efficacy of GT3. MDPI 2017-12-28 /pmc/articles/PMC5796029/ /pubmed/29283379 http://dx.doi.org/10.3390/ijms19010079 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cheema, Amrita K.
Mehta, Khyati Y.
Fatanmi, Oluseyi O.
Wise, Stephen Y.
Hinzman, Charles P.
Wolff, Josh
Singh, Vijay K.
A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol
title A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol
title_full A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol
title_fullStr A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol
title_full_unstemmed A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol
title_short A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol
title_sort metabolomic and lipidomic serum signature from nonhuman primates administered with a promising radiation countermeasure, gamma-tocotrienol
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796029/
https://www.ncbi.nlm.nih.gov/pubmed/29283379
http://dx.doi.org/10.3390/ijms19010079
work_keys_str_mv AT cheemaamritak ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT mehtakhyatiy ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT fatanmioluseyio ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT wisestepheny ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT hinzmancharlesp ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT wolffjosh ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT singhvijayk ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT cheemaamritak metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT mehtakhyatiy metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT fatanmioluseyio metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT wisestepheny metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT hinzmancharlesp metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT wolffjosh metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol
AT singhvijayk metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol